Platinum refractory

Author: xebl

August undefined, 2024

Webb31 mars 2024 · Patients with platinum-resistant ovarian cancer have long represented an area of unmet medical need; standard-of-care treatments such as pegylated liposomal doxorubicin and topotecan have... Webb28 jan. 2024 · Participant has platinum-resistant (progression within one to six months after completing platinum-based therapy) or platinum refractory disease (progression …

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in ...

WebbThe platinum-refractory cohort was closed early due to futility. Median PFS and OS in cohort the platinum-sensitive cohort were 3.7 months and 8.0 months, respectively, with an ORR of 13.8%. Pazopanib is a tolerable and effective salvage treatment in patients with platinum-sensitive SCLC. WebbPlatinum or platinum alloy is sprayed onto the surface of a refractory material to form a platinum or platinum alloy coating. This provides dramatically improved glass corrosion resistance of the refractory material, making it possible to more effectively manufacture glass with a smaller amount of precious metals, compared with conventional ... javelins usmc

再発卵巣癌治療の最新知見【婦人科腫瘍学会2012】：日経メディ …

WebbKey Points. Question In patients with platinum-refractory metastatic urothelial cancer, is nab-paclitaxel more effective and better tolerated than paclitaxel?. Findings In this randomized phase 2 clinical trial with 199 patients randomized to nab-paclitaxel or paclitaxel, there was no significant difference between nab-paclitaxel vs paclitaxel for … WebbFor the analysis of HNC patients treated with platinum-based regimens, platinum-refractory populations were defined as patients with records of other systemic therapy within 6 months from the last dosing date of the previous platinum agent in any setting, because information on disease progression, such as radiographs, is not available from … WebbPlatinum refractory cancer continues to grow while on treatment or recurs within a month after the last platinum treatment. Non-platinum drugs are prescribed to treat it. In addition to standard chemotherapy, there are … javelin training program pdf

The efficacy and safety of apatinib plus capecitabine in platinum ...

Addition of Ipilimumab to Nivolumab in Recurrent or Metastatic …

Webb10 aug. 2012 · Ovarian cancer patients with platinum-resistant and -refractory disease have the lowest response rates to salvage chemotherapy. Various chemotherapeutic agents, such as paclitaxel, liposomal doxorubicin, topotecan, docetaxel, platinum, etoposide, ifosfamide, gemcitabine, and vinorelbine, are available and result in response … WebbIn the population with platinum-refractory R/M SCCHN, rates of any grade and grade 3 or 4 serious TRAEs were 8.2% (13 of 158 patients) and 5.7% (9 of 158), respectively, with nivolumab plus ipilimumab vs 9.8% (8 of 82) and 3.7% … javelin\u0027sWebbIn patients with relapsed ovarian cancer, the overall response rates on treatment with topotecan range from 19%-33% in platinum-sensitive patients, 14%-18% in platinum-resistant patients, and 5%-11% in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17% in refractory and 48% in sensitive patients ... javelin tracking

"Webb9 jan. 2024 · Testicular germ cell tumors are chemosensitive with very high cure-rates even in the metastatic setting. However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite salvage treatments, and with no effective alternative therapies. Immunotherapy, notably with PD-1 inhibitors, … " - Platinum refractory

Platinum refractory

Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent …

WebbBackground: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M … Webb6 juli 2024 · In April 2024, the National Institute for Health and Care Excellence (NICE) recommended pembrolizumab for use within the Cancer Drugs Fund for treating patients …

Did you know?

WebbFor the analysis of HNC patients treated with platinum-based regimens, platinum-refractory populations were defined as patients with records of other systemic therapy … WebbPurpose: In general, 50 % up to 80 % of metastasized germ cell tumor patients can be cured by platinum-based chemotherapy. However, 3-5 % of patients will still die of platinum …

WebbRefractory Primary Peritoneal Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Platinum-Resistant Primary Peritoneal Carcinoma Recent clinical studies Etiology Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter …

Webb6 maj 2024 · Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis Head and Neck Cancer JAMA Network Open JAMA Network Webb12 apr. 2024 · KEY POINTS Among patients with platinum-refractory disease, objective response rates were 13.2% with the combination vs 18.3% with nivolumab alone. Among patients with platinum-eligible disease, objective response rates were 20.3% vs …

Webb25 jan. 2024 · Three additional CPIs have now been studied in and received accelerated FDA approval for the platinum-refractory population of mUC – nivolumab, durvalumab, and avelumab [ 5, 9, 10 ]. In the CheckMate 275 phase II trial of nivolumab, PD-L1 status was determined using the 28–8 rabbit antibody (Dako/Agilent, CA, USA).

WebbAbstract. Platinum drug-based chemotherapy plays a dominant role in OC (ovarian cancer) treatment. The expression of DNA damage repair (DDR) genes is critical in distinguishing drug-sensitive and drug-refractory patients, as well as in the development of drug resistance in long-term treated patients. javelin traduzioneWebb11 apr. 2024 · The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is 6 to 15 months depending on patient- and disease-related factors. Symptom-directed care plays an important role in the management of these patients. javelin track days ukWebb1 apr. 2024 · All patients were platinum-refractory, with the exception of five patients who received apatinib as first-line (one patient had an active hepatitis B infection; one patient who was older than 70 years with moderate hypertension; one patient had G1 thrombocytopenia and G2 leukopenia; and two patients declined chemotherapy due to … javelin\\u0027sWebbEligible pts had ED-SCLC, disease progression (PD) during or within 90 days of completing first-line platinum-based CT, WHO/ECOG performance status 0 or 1, and a life expectancy ≥8 weeks. Pts enrolled in Arm A received D 1500 mg + T 75 mg IV q4w for up to 4 months, followed by D 1500 mg IV q4w monotherapy from Week 16 until PD or discontinuation. javelins weaponWebb3 apr. 2024 · The innovative Kell Process allows companies with challenging platinum, base metal, refractory gold and polymetallic ore bodies to benefit from this highly efficient hydrometallurgical Kell ... javelin\u0027s 01Webb30 maj 2024 · Univariable and multivariable analyses were performed to assess the effect of patient characteristics (time from diagnosis to platinum resistance, OC subtype, … javelin\\u0027s 0Webb1 juli 2024 · Platinum-Refractory. Definition. A finding indicating that a cancer is refractory to platinum therapy. For non-gynecologic cancers, the terms ""platinum-refractory"" and … javelin trans am car